Tobingregorypic

Gregory J. Tobin, PhD

Gregory J. Tobin, PhD Dr. Tobin is the Chief Scientific Officer of Lantern Pharma, Inc. and President of Biological Mimetics, Inc. and is an immunologist, virologist, and cancer biologist. While at the National Cancer Institute (NIH, USA), Dr. Tobin developed animal models for human diseases, designed and tested small molecule therapeutics for leukemia, and worked on cancer vaccines and immunotoxins. Greg’s work at BMI centers around applying rational antigen design technologies to build better vaccines. A single antigen rhinovirus vaccine candidate, for example, stimulates antibodies that neutralize 41 of the 61 serotypes tested and is under continued development. Dr. Tobin and others at BMI founded Lantern Pharma, Inc. in 2013 to develop cancer therapeutics using a biomarker approach. Lantern Pharma has in-licensed two drugs, LP-184 and Tavocept, and out-licensed Irofulven to Oncology Venture. Initial biomarker studies have utilized drug sensitivity and molecular profiles from cell culture-based assays. Lantern Pharma is expanding the biomarker identification technology with the analysis of fresh tumor biopsy tissues. The Company is identifying for acquisition additional therapeutics which have shown good safety profiles in Phase 2 or 3 trials but low response rates. By developing biomarker profiles for these drugs, Lantern Pharma will be able to identify the patients that are most likely to respond. Initial biomarker identification methods have used a statistical algorithm to correlate drug sensitivity with gene expression levels. More recently, Lantern Pharma has developed more efficient computational programs that are able to identify and order a large number of potential biomarkers and then reduce this number to a manageable level (10-20 genes) by rapidly re-calculating the prediction confidence as genes are weeded out based on a series of 19 “profiles” that include pathway, proximity, and other analyses. Lantern Pharma is currently analyzing patient data from multiple standard-of-care treatments to identify biomarkers that predict response outcomes of licensed therapeutics.